New preclinical study shows antibody therapy could offer treatment path for genetic form of ALS
In 2012, one in eight elderly Americans was diagnosed with Alzheimer’s disease, according to the Alzheimer’s Association 2012 Report. While deaths caused by other major illnesses are continuously declining, deaths caused by neurodegenerative diseases are increasing dramatically. In addition, millions of people provide unpaid care for one of the 36 million persons with Alzheimer’s disease or other dementias worldwide. In addition, patient numbers are projected to increase to 115 million by 2050, based on demographic changes in industrialized as well as emerging countries, increasing early diagnoses of these disorders, and increased prevention markets. Neurimmune aims at the development of disease-modifying treatments for such disorders.